{
    "organizations": [],
    "uuid": "025a71f84ea7509c183e756754785d2e393cdf4a",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/28/business-wire-biogen-to-report-first-quarter-2018-financial-results-on-april-24-2018.html",
    "ord_in_thread": 0,
    "title": "Biogen to Report First Quarter 2018 Financial Results on April 24, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2018 financial results on Tuesday, April 24, 2018, before the financial markets open.\nFollowing the release of the financials, the Company will host a live webcast with Biogen management from 8:30-9:30 am ET. To access the live webcast, please go to the investors section of Biogen’s website. Following the live webcast, an archived version of the call will be available on the website.\nAbout Biogen\nAt Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissman, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post information that may be important to investors on our website at www.biogen.com . To learn more, please visit www.biogen.com and follow us on social media – Twitter , LinkedIn , Facebook , YouTube .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180328006032/en/\nBiogen\nKaren Jewell, 781-464-2442\nInvestor Relations\nSource: Biogen Inc.",
    "published": "2018-03-29T00:01:00.000+03:00",
    "crawled": "2018-03-29T01:44:29.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "business",
        "wire",
        "biogen",
        "nasdaq",
        "biib",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "tuesday",
        "april",
        "financial",
        "market",
        "open",
        "following",
        "release",
        "financials",
        "company",
        "host",
        "live",
        "webcast",
        "biogen",
        "management",
        "et",
        "access",
        "live",
        "webcast",
        "please",
        "go",
        "investor",
        "section",
        "biogen",
        "website",
        "following",
        "live",
        "webcast",
        "archived",
        "version",
        "call",
        "available",
        "website",
        "biogen",
        "biogen",
        "mission",
        "clear",
        "pioneer",
        "neuroscience",
        "biogen",
        "discovers",
        "develops",
        "delivers",
        "worldwide",
        "innovative",
        "therapy",
        "people",
        "living",
        "serious",
        "neurological",
        "neurodegenerative",
        "disease",
        "founded",
        "one",
        "world",
        "first",
        "global",
        "biotechnology",
        "company",
        "charles",
        "weissman",
        "heinz",
        "schaller",
        "kenneth",
        "murray",
        "nobel",
        "prize",
        "winner",
        "walter",
        "gilbert",
        "phillip",
        "sharp",
        "today",
        "biogen",
        "leading",
        "portfolio",
        "medicine",
        "treat",
        "multiple",
        "sclerosis",
        "introduced",
        "first",
        "approved",
        "treatment",
        "spinal",
        "muscular",
        "atrophy",
        "focused",
        "advancing",
        "neuroscience",
        "research",
        "program",
        "alzheimer",
        "disease",
        "dementia",
        "multiple",
        "sclerosis",
        "neuroimmunology",
        "movement",
        "disorder",
        "neuromuscular",
        "disorder",
        "pain",
        "ophthalmology",
        "neuropsychiatry",
        "acute",
        "neurology",
        "biogen",
        "also",
        "manufacture",
        "commercializes",
        "biosimilars",
        "advanced",
        "biologics",
        "routinely",
        "post",
        "information",
        "may",
        "important",
        "investor",
        "website",
        "learn",
        "please",
        "visit",
        "follow",
        "u",
        "social",
        "medium",
        "twitter",
        "linkedin",
        "facebook",
        "youtube",
        "view",
        "source",
        "version",
        "http",
        "biogen",
        "karen",
        "jewell",
        "investor",
        "relation",
        "source",
        "biogen",
        "inc"
    ]
}